INmune Bio Inc (INMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.30M
Last updated: Nov 17, 2026 at 4:26 PM ET
INmune Bio Inc (INMB) Statistics
INmune Bio (INMB) has a market cap of $29.30M and an enterprise value of $12.97M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $16.33M more cash than debt, 55.73% of its market cap.
Total Valuation
Enterprise value is 55.73% below the market cap, as cash exceeds debt.
| Market Cap | $29.30M |
|---|---|
| Enterprise Value | $12.97M |
| Latest price (Nov 17, 2026) | $0.96 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 32.39% over 52 weeks and trades 43.53% below its 50-day average.
| Beta (1Y) | 2.57 |
|---|---|
| 52-Week Change | -32.39% |
| 1-Month Change | -37.66% |
| 3-Month Change | -56.95% |
| 6-Month Change | -31.91% |
| 5-Year Change | -92.12% |
| Total Return (1Y) | -32.39% |
| Total Return (3Y CAGR) | -49.39% |
| Total Return (5Y CAGR) | -41.27% |
| Max Drawdown (1Y) | -62.29% |
| Max Drawdown (3Y) | -93.24% |
| Sharpe Ratio (1Y) | -0.60 |
| Correlation with SPY (1Y) | 0.48 |
| 50-Day Average | $1.70 |
| 200-Day Average | $1.61 |
| 52-Week Range | $0.89 to $2.60 |
| RSI (14 Days) | 20.4 |
| Average Volume (20 Days) | 335.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.41x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.41x |
|---|---|
| Quick Ratio | 6.41x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -92.21% over the last 12 months, against a 5-year average of -97.99%.
| Return on Equity (ROE) | -92.21% |
|---|---|
| Return on Assets (ROA) | -77.49% |
| ROE (5Y Average) | -97.99% |
| ROA (5Y Average) | -72.95% |
| ROIC (5Y Average) | -70.76% |
Scores
INMB has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$56.00K |
| Operating Income | -$17.77M |
| Pretax Income | -$16.67M |
| Net Income | -$16.67M |
| Reported EPS (TTM) | -$0.60 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.01% of the $21.51M in total assets.
| Cash and Equivalents | $16.33M |
|---|---|
| Total Debt | $0 |
| Net Cash | $16.33M |
| Net Cash Per Share | $0.59 |
| Working Capital | $15.79M |
| Shareholder Equity | $18.07M |
| Book Value Per Share | $0.65 |
| Total Assets | $21.51M |
| Total Liabilities | $3.44M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$12.91M |
|---|---|
| FCF Per Share | -$0.42 |
| Depreciation and Amortization | $247.00K |
Trailing 12 months through Sep 30, 2026.
Growth
Revenue fell 48.87% a year over 3 years.
| Revenue Growth (3Y CAGR) | -48.87% |
|---|---|
| Revenue Growth (5Y CAGR) | +35.37% |
| Book Value Per Share Growth (2Y CAGR) | -34.78% |
| Tangible Book Per Share Growth (2Y CAGR) | -12.67% |
Dividends and Yields
INMB does not pay a dividend.
| Buyback Yield | -3.92% |
|---|---|
| Shareholder Yield | -3.92% |
Analyst Forecast
Consensus estimates put revenue growth at 1642.41% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1642.41% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INMB
What is INMB's market cap?
INmune Bio has a market cap of $29.30M. Its enterprise value, which adds debt and subtracts cash, is $12.97M.
How many shares of INMB are outstanding?
INmune Bio has 27.81M shares outstanding. The count is up 4.60% from a year earlier.
Does INMB pay a dividend?
No. INmune Bio does not pay a dividend.
How much debt does INMB have?
INmune Bio has $0 of total debt and $16.33M of cash and equivalents, a net cash position of $16.33M.
INMB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors